Background
Bipolar disorder (BD) has substantial morbidity and incompletely understood
neurobiological underpinnings.
Objective
To investigate brain chemistry in medication-free individuals with BD.
Design
Two-dimensional proton echo-planar spectroscopic imaging (PEPSI) (32
× 32, 1-cm3 voxel matrix) acquired axially through the cingulate
gyrus was used to quantify regional brain chemistry.
Setting
The Center for Anxiety and Depression at the University of Washington
in Seattle and the Bipolar Research Programs at McLean Hospital and the Massachusetts
General Hospital in Boston.
Participants
Thirty-two medication-free outpatients with a diagnosis of BD type I
(BDI) or BD type II (BDII), predominantly in a depressed or mixed-mood state,
were compared with 26 age- and sex-matched healthy controls.
Main Outcome Measures
Tissue type (white and gray) and regional analyses were performed to
evaluate distribution of lactate; glutamate, glutamine, and γ-aminobutyric
acid (Glx); creatine and phosphocreatine (Cre); choline-containing compounds
(Cho); N-acetyl aspartate; and myo-inositol. Chemical relationships for diagnosis and mood state were
evaluated.
Results
Patients with BD exhibited elevated gray matter lactate (P = .005) and Glx (P = .007) levels; other
gray and white matter chemical measures were not significantly different between
diagnostic groups. Isolated regional chemical alterations were found. An inverse
correlation between 17-item Hamilton Depression Rating Scale scores and white
matter Cre levels was observed for BD patients.
Conclusions
Gray matter lactate and Glx elevations in medication-free BD patients
suggest a shift in energy redox state from oxidative phosphorylation toward
glycolysis. The possibility of mitochondrial alterations underlying these
findings is discussed and may provide a theoretical framework for future targeted
treatment interventions.
Bipolar disorder (BD) is a psychiatric disorder characterized by mooddisturbances with recurrent episodes of mania, hypomania, and depression.1 Bipolar disorder can be differentiated into clinicalsubtypes of BD type I (BDI), characterized by at least 1 episode of pure mania,and BD type II (BDII), characterized by less clinically severe hypomania andmajor depressive episodes.2,3 Thereis an approximately 1% prevalence rate for BDI among the adult population;the prevalence rate may be somewhat higher for BDII.4,5 Neurobiologicalmechanisms are thought to underlie BD, and there is evidence of a familial,and presumably genetic, predisposition for the disorder.6
Serendipitous observations of the mood-stabilizing effect of lithiumsalts and later certain anticonvulsants, such as valproic acid, have substantiallyimproved the prognosis of patients with BD. Despite this progress, these medicationsare not universally effective, and many individuals are unable to toleratetreatment-related adverse effects.6,7 Inaddition to incomplete clinical response, relapse and recurrence remain commonclinical problems.8,9 A recentsurvey of BD lifetime financial burden in the United States found associatedcosts to be up to $625 000 per patient, depending on treatment refractorinessand chronicity of symptoms.10 Bipolar disordercontinues to be associated with substantial morbidity and mortality, rankingworldwide among psychiatric disorders behind only unipolar depression andalcohol abuse for related disabilities and overall economic load of the illness.11,12
Research conducted over several decades investigating biomarkers relatedto BD provides evidence for widespread alterations of multiple neurotransmitteror signal induction systems and physiological processes associated with thedisorder, as reviewed by Manji and Lenox.13 Increasingly,imaging techniques are being applied to better establish brain mechanismsunderlying the etiology of BD. Positron emission tomography studies, usedto characterize patterns of regional metabolism or cerebral blood flow inmood disorders, typically find regional or widely distributed abnormalitiesof reduced blood flow and metabolism in association with depressed mood states,including BD-related depression.14-17 Magneticresonance (MR) imaging studies, as reviewed by Strakowski et al,18 variablyfind evidence of reduced regional gray matter volumes associated with BD.16,19-23 Differingsubcortical patterns of structural abnormalities may occur across the spectrumof affective disorders; for example, basal ganglia and amygdalar enlargementare observed in BD,19,24 whereasvolumes of these structures may be reduced in unipolar depression.25,26 Similarly, neuroanatomic findingshave been reported to distinguish BD clinical subtypes, such as the observationof lateral ventricular enlargement in BDI but not BDII patients.27
Magnetic resonance spectroscopy, an imaging modality related to MR imaging,provides an in vivo tissue-based measure of brain chemistry using clinicalMR image scanners that is safe, noninvasive, and reproducible.28,29 Forneuropsychiatric applications at 1.5 T, as reviewed elsewhere,30-32 hydrogenH1 (1H) MR spectroscopy can detect and identify subtle alterationsin brain chemical composition, despite normal-appearing structure, throughquantifying the resonance frequency of certain 1H-containing chemicalcompounds that include the combined resonances of creatine and phosphocreatine(Cre); choline-containing compounds (Cho); N-acetylmoieties predominately composed of N-acetyl aspartate(NAA); myo-inositol (mI), which also contains somecontribution from scyllo-inositol at 1.5 T; the overlapping resonances ofglutamine, glutamate, and γ-aminobutyric acid (Glx); and lactate. Thedevelopment of rapid MR spectroscopy techniques, such as proton echo-planarspectroscopic imaging (PEPSI), allows fast, clinically feasible acquisitionof 2-dimensional images of brain chemical composition.33 Short-echotime (TE) measurements (eg, 20 milliseconds) can be acquired using PEPSI thatprovide a more accurate appraisal of brain chemical concentration, particularlyas some disease states, such as autism, can alter tissue relaxation characteristicsand substantially affect spectral quantification at longer TEs.34
The purpose of this study was to characterize brain chemical compositionin medication-free BD patients compared with age- and sex-matched healthycontrols (HCs). To ensure adequate numbers of medication-free participants,a dual-site study was conducted between Boston, Mass, and Seattle, Wash. Medication-freeBD patients were studied, because prior work35-41 suggestssecondary effects of mood stabilizers or antidepressants on MR spectroscopy–detectablechemicals and gray matter volume that could confound interpretation of findings.We evaluated diagnostic relationships for chemicals detectable by 1H-MRspectroscopy, including Cho, Cre, mI, Glx, and NAA, to extend prior work thatfound metabolic alterations in mood disorders. The present investigation furthersought to exploit the within-subject multiple voxel sampling acquired withPEPSI to evaluate whether lactate, a potential indicator of redox status butwith a low signal-to-noise ratio in the resting state, was altered in BD.To assess tissue-type specificity for chemical findings, gray and white mattercompartments were evaluated separately using established regression methods.42-44 We report tissue-specificand regional brain chemical findings in BD patients vs HCs, relationshipsto mood state, and clinical subtypes of BDI and BDII.
Participants were 32 adults with BD (14 men, 18 women; mean ±SD age, 30.3 ± 10.8 years) and 26 HCs (12 men, 14 women; mean ±SD age, 31.9 ± 7.7 years). Participants were recruited through theBipolar Research Programs at McLean Hospital and the Massachusetts GeneralHospital (BD patients = 15; HCs = 16) or the University of Washington Centerfor Anxiety and Depression (BD patients = 17; HCs = 10). Written, informedconsent, approved by either McLean Hospital and Massachusetts General Hospital,Harvard University, or the University of Washington Human Subjects ReviewBoards, was obtained from each participant before study enrollment. All participantstolerated the scanning procedure, but 3 BD patients (1 man, 2 women) and 2HCs (2 men) had invalid studies due to technical acquisition problems or movementartifacts and were not included in the statistical analyses. Additionally,only long-echo MR spectroscopy data (lactate) were acquired for 1 BD patient.There were no significant differences in sex distribution (χ21 = 0.11, P = .75) or age (t51 = 0.73, P = .47) between diagnosticgroups.
Psychiatric diagnosis was established through a DSM-IV–based structured psychiatric interview by skilled clinicians (D.L.D.,C.D., A.L.S.). These clinicians also established diagnostic agreement betweensites before study inception and consensus for individual subject inclusionthroughout the study. The BD patients did not meet other DSM-IV Axis I diagnoses, including lifetime alcohol and/or other drugdependency or abuse within 6 months of study entrance. All participants weremedication free for 8 weeks or longer before the study. Participants wereoutpatients seeking treatment and had not stopped treatment to participatein the study. Of the 29 BD patients with valid studies, 26 had never beentreated with mood-stabilizing medications, and the 3 previously treated BDpatients (2 taking lithium and 1 taking valproic acid) had not been takingmood stabilizers for at least 1 year. Twelve BD patients, including the 3previously taking mood stabilizers, had been prescribed antidepressants inthe past but had not been taking them for at least 8 weeks or longer beforethe study. No patients had previously been treated with antipsychotic medication.The results of urine toxicology screening obtained before the study were negativefor psychoactive substances. Evidence of clinically significant medical problemsthrough medical history, laboratory workup, including thyroid studies, andphysical examination that evaluated for cerebral vascular disease, pulmonarydisease, endocrine disorders, severe sensory or motor impairments (deaf orblind), documented head trauma, or metal implants was exclusionary for participation.Healthy controls had no current symptoms or medical history consistent witha DSM-IV Axis I diagnosis, and there was no historyof clinically significant psychiatric disorders in their first-degree relatives.
Subtype classification of BD patients into BDI (n = 11; 5 men, 6 women;mean ± SD age, 31.9 ± 6.1 years) or BDII (n = 17; 7 men, 10women; mean ± SD age, 28.9 ± 10.5 years) was determined at studyentrance by structured psychiatric interview. One participant was not classifiedand excluded from further analysis. Mood state before MR imaging or MR spectroscopywas assessed using the 17-item Hamilton Depression Rating Scale (HAM-D)45 and the Young Mania Rating Scale (YMRS).46 The mean ± SD HAM-D score for the BD patientswas 17.7 ± 8.6 (BDI, 20.0 ± 8.2; BDII, 16.1 ± 9.0) comparedwith 1.2 ± 1.1 for the HCs. The mean ± SD YMRS score for theBD patients was 6.5 ± 7.7 (BDI, 9.7 ± 9.1; BDII, 4.6 ±6.4) compared with 0.3 ± 0.5 for HCs. The BD patients had an averageillness duration of 13.5 ± 10.2 years (range, 0.5-33.0 years), with13.6 ± 18.1 depressive episodes and 7.3 ± 7.6 hypomanic manicepisodes.
Mr imaging and mr spectroscopy acquisition
The PEPSI studies were performed using clinical 1.5-T SIGNA whole-bodyscanners (GE Medical Systems, Milwaukee, Wis), both equipped with version5.8 Genesis operating software. Experimental receive-only linear birdcagecoils, designed and built at the University of Washington, that provided approximately√√2 enhanced signal-to-noise ratio and improved coil homogeneityover conventional quadrature head coils (Cecil Hayes, PhD, unpublished data,1996) were used at both sites. The coil design incorporates a built-in headholder to minimize head motion during scanning.
Axial proton density and T2-weighted MR images were used for anatomiclocalization and tissue segmentation (TE, 13/91 milliseconds; repetition time[TR], 2000 milliseconds; field of view (FOV), 22 cm; matrix, 256 × 160;slice thickness, 3 mm). For PEPSI studies, anatomic volumes were acquiredfrom an axial section centered on the anterior cingulate (Figure 1). The PEPSI pulse sequence has been described in detailelsewhere.33,47 Two TEs and standardparameters were used for data acquisition (TE, 20/272 milliseconds; TR, 2000milliseconds; spatial matrix, 32 × 32; nominal voxel size, 1 cm3; FOV, 22 cm; slice thickness, 20 mm). Magnetic resonance spectroscopydata were acquired in scan blocks (20-millisecond chemical image: 4 numbersof excitation/[NEX]; 4-minute scan time; 272-millisecond chemical image: 8NEX; 8-minute scan time; 20-millisecond water image: 2 NEX; 2-minute scantime), totaling approximately 20 minutes, including shimming and scan setup.A full echo was collected for 20-millisecond chemical data and a partial echofor 272-millisecond chemical data, the latter necessitating a magnitude calculation(√[real2 + imaginary2]) for data reconstruction.47 Unsuppressed short-echo water scans were also collectedfrom the identical axial slice location (TE, 20 milliseconds; TR, 2000 milliseconds)for referencing both metabolite scans as previously described.34
The PEPSI chemical images were analyzed using software developed atthe University of Washington that used the LCModel package for spectral fitting48 (Figure 1).Consistent with our prior work to optimize LCModel parameters34 andto standardize measurements between sites, phantoms with known concentrationsof brain chemicals were prepared at McLean Hospital and scanned at variousacquisition parameters, and basis sets were created as detailed in the LCModelmanual. All data sets were analyzed unbiased by user interaction on workstations(SGI Octane; Silicon Graphics Inc, Mountain View, Calif) running IRIX system6.5.8.
To calculate chemical concentrations and relaxation estimates, LCModelwater amplitudes were adjusted by water molarity estimates and attenuationconstants were then multiplied by the partial volume tissue fraction. Chemicalamplitude maps were adjusted for the differential relaxation between in vitro(phantoms) and in vivo estimates for Cre, Cho, and NAA, which served to scalechemical output similar to our previous work.34 Metaboliteswere then multiplied by the inverted partial-volume–corrected waterterm to yield chemical concentration.49
Absolute T2 calculations from the short- and long-echo PEPSI data couldnot be accurately determined, because long-echo data were acquired as a partialecho, requiring a magnitude calculation for reconstruction. Thus, a relativemeasure of T2 relaxation (T2r) for each region was calculated from chemicalsmeasured at both short and long TEs (Cre, Cho, and NAA), as previously described.34
Because short-echo data afford the least biased estimation of chemicalconcentration, long-echo data were used only for lactate measurements andT2 relaxation time calculations.28,34,47 Chemicalmeasures from each spectral array were determined from all valid voxels foreach individual participant to achieve maximum signal-to-noise ratios. Thenumber of valid voxels from the 32 × 32 spectra array acquired per subjectwas not significantly different comparing BD and HC groups for all chemicalmeasurements (t<0.86 and P>.38for all).
Dual-echo axial images were skull stripped and then segmented usingmultispectral analytic tools within an image manipulation and visualizationpackage (Analyze; Mayo Clinic, Rochester, Minn). Specifically, sample regionsof gray matter, white matter, and cerebrospinal fluid (CSF) (eg, intraventricularCSF) were manually selected by a single rater (I.K.L.) blinded to patientdiagnosis. These pure exemplars, unbiased by partial volume, were used asstarting points for gaussian classification. Following segmentation, a secondscript written in MATLAB, a computer language used for array computation andvisualization, was used to offset the images to magnet center using MR imageheader coordinates and extract images within the PEPSI volume. Because PEPSIdata sets are acquired at magnet center, aligning anatomic images in thisway results in accurate registration.
The CSF and tissue maps were processed as previously detailed,34,50 including summation of images withinthe PEPSI volume, spatial filtering, and array reduction to match the chemicalarray spatial resolution (32 × 32). On a voxel-by-voxel basis, CSF datawere used for partial volume correction of metabolite quantification. Partialvolume tissue estimates of the PEPSI slab were similar between groups (BDpatients, 0.95 ± 0.02; HCs, 0.96 ± 0.01; t50 = 0.62; P = .54). For regressionanalyses, white and gray matter maps were used. The percentage of gray mattercomprising the axial slab studied using PEPSI was also similar between groups(BD patients, 52.96% ± 4.71%; HCs, 51.78% ± 4.98%; t50 = .88; P = .38). For each participant,using all valid spectroscopy voxels, regression analyses were performed comparingthe fractional tissue volume (percentage of gray or white matter per voxel)to concentration and relaxation values. This approach, similar to that usedby other investigators,42-44 takesadvantage of the large number of voxel samples obtained using spectroscopicimaging to calculate estimates of pure tissue neurochemistry (regression intercepts)and the relationship between tissue classes (regression slope). Characteristicchemical regression plots from an individual BD patient are shown in Figure 2.
Region-of-interest analyses
For region-of-interest (ROI) selection, the PEPSI voxel grid (32 ×32 matrix) was graphically overlaid onto the axial MR image data set for selectinganatomic loci: frontal white matter left and right, cingulate left and right,caudate left and right, putamen left and right, thalamus left and right, insulaleft and right, parietal white matter left and right, and midline occiput(Figure 3). A rater (S.D.F.) blindedto patient diagnosis recorded the voxel position for each ROI into a texttemplate, and a MATLAB script was used to extract concentration data by regioninto a tabulated text file. For nuclei, the voxel chosen was centered on theanatomic target structure; if no corresponding voxel could be selected, amissing value was entered. In other larger anatomic regions, ROIs were averagedacross contiguous voxels to maximize signal-to-noise ratio.
Stepwise multivariate linear regression using SPSS statistical softwareversion 11 (SPSS Inc, Chicago, Ill) assessed interrelationships between categoricalvariables of psychiatric diagnosis and clinical subtype diagnosis with continuouspredictor variables of chemical concentrations (20 milliseconds for Cho, Cre,NAA, mI, and Glx; 272 milliseconds for lactate). Chemical T2r (Cho, Cre, andNAA) was separately modeled. Regional chemical composition by diagnosis wasevaluated using independent t tests. For BD patients,mood state rating scales in relationship to chemical measures were evaluatedusing the Pearson r. Significance was fixed at a2-tailed α of .05. Bonferroni correction for ROI analyses was appliedby dividing the α level by number of regions assessed (adjusted α= .003) and for mood assessment by number of gray-white chemical measures(adjusted α = .004). Values are presented as mean ± SD. Regionaland diagnostic subgroup analyses by mood were not performed because of powerconsiderations.
Brain chemical concentrations by tissue type are given for each diagnosticgroup in Table 1. A significantmodel observed for gray matter chemical measures and diagnosis (BD patientsvs HCs) (F2,51 = 8.34, P = .001) was bestpredicted by elevated lactate (19.75% increase, β = .37, t = 2.96, P = .005) and Glx levels (10.01%increase, β = .35, t = 2.83, P = .007) in BD patients; other gray matter chemicals were nonsignificantwithin the model (β<.28, t≤1.07, P ≥.32 for all). The model for white matter chemicalsand diagnosis did not reach statistical significance (F1,51 = 3.61, P = .06). The models for diagnosis and gray matter T2r(F1,51 = 1.06, P = .31) or white matterT2r (F1,51 = 3.59, P = .07) also did notreach statistical significance. Similarly, the models for diagnosis and chemicalregression slopes (F1,51 = 3.12, P = .08)(Table 1) or T2r regression slopes(F1,51 = 0.30, P = .59) did not reachstatistical significance.
Brain chemical ROI relationships were assessed (Figure 3). Chemical alterations included increased Glx levels inthe left cingulate (t39 = 2.09, P = .04) and increased Cho levels in the left caudate (t37 = 2.71, P = .01)in BD patients. The BD group also exhibited increased Cho levels in the rightputamen (t50 = 2.43, P = .02), increased NAA levels in the left putamen (t52 = 3.57, P = .001), and increasedGlx levels in the left insula (t51 = 3.32, P = .002). After Bonferroni correction for the multipleregions compared (adjusted α = .003), only putamen and insula findingsremained statistically significant.
The BD patients differentiated into BDI and BDII clinical subtypes werefurther evaluated for gray and white matter chemical differences (Table 2). Comparing BDI patients and HCs,a significant model for gray matter chemicals (F1,33 = 12.24, P = .001) was predicted by elevated lactate levels in theBDI subgroup (31.45% increase, β = .53, t =3.50, P = .001); other gray matter chemicals didnot significantly contribute to the model (β<.19, t≤1.25, P≥.22 for all). No significantmodel for white matter chemicals and BDI vs HC diagnosis was found (F1,33 = 0.59, P = .74). There were also no statisticallysignificant models for gray or white matter T2r and diagnosis (F<1.23, P>.27 for all). Modeling chemical regression slopes, asignificant model (F1,33 = 6.39, P = .02)was predicted by an increased lactate white-gray regression slope in BDI patients(0.06 ± 0.50 vs −0.35 ± 0.51, β = .41, t = 2.53, P = .02).
Comparing BDII patients and HCs, a statistically significant model forgray matter chemicals (F2,40 = 7.13, P =.002) was predicted by elevated Glx levels (13.97% increase, β = .47, t = 3.29, P = .002) and trendelevated lactate levels (11.3% increase, β = .24, t = 1.70, P = .10) in the BDII subgroup; othergray matter chemicals did not contribute to the model (β<.11, t≤0.69, P>.49 for all). A significantmodel for BDII compared with HCs for white matter chemicals (F1,40 =5.47, P = .03) was predicted by elevated Glx levelsin the BDII subgroup (11.6% increase, β = .35, t =2.34, P = .03); other white matter chemicals didnot contribute to the model (β<.23, t<1.39, P>.17 for all). Additionally, significant models observedfor gray matter T2r (F1,40 = 5.27, P =.03) were predicted by shortened Cho T2r (decreased 15.1% from HCs, β= .35, t = 2.30, P = .03)and white matter T2r (F1,40 = 4.13, P =.05) predicted by shortened Cho T2r (decreased 9.9% from HCs, β= .31, t = 2.03, P = .05)in BDII patients. The model for white-gray regression slope and BDII vs HCdiagnosis did not reach statistical significance (F1,40 = 3.21, P = .08).
Clinical mood state of BD patients at time of scanning was evaluatedin relationship to averaged gray-white matter chemical measures using thePearson r. An inverse correlation with HAM-D scoreswas found for white matter Cre (r28 =−0.55, P = .003); no significant interactionswere observed between HAM-D scores and other gray or white matter chemicals(r<.33, P>.09). The YMRSscores were inversely correlated with mI levels both in gray matter (r28 = −0.46, P =.01) and white matter (r28 = −0.42, P = .03); no significant relationships were observed forother gray or white matter chemicals (r<.36, P≥.06). After Bonferroni correction for the number ofgray and white matter chemical measures (adjusted α = .004), a significantinteraction between white matter Cre and HAM-D scores remained (Figure 4).
Medication-free BD patients demonstrated elevated lactate and Glx levelsin gray matter compared with the HC group; other gray-white matter chemicalconcentrations, chemical T2r measures, and chemical regression slopes betweenwhite and gray matter were not significantly different between groups. TheBDI patients demonstrated elevated gray matter lactate and altered lactatetissue distribution that was shifted toward gray matter compared with HCs;the BDII patients exhibited elevated Glx and trend elevated lactate levelsin gray matter, as well as elevated white matter Glx levels. The BDII patientsadditionally demonstrated shortening of Cho T2r in both gray and white matter.Chemical differences for BDI and BDII patients may reflect intrinsic diagnosticdifferences or illness severity, because BDI patients had higher HAM-D andYMRS scores. A significant inverse correlation also was found for white matterCre and HAM-D scores in BD patients. We believe that this is the first reportof elevated gray matter lactate levels in BD. Several recent single-voxel 1H-MR spectroscopy studies of BD also have reported elevated Glx levels.51,52 Lactate levels in those studies werenot reported because of characteristics of the acquisition parameters andsignal-to-noise ratio considerations.
Although our line-fitting analyses fit the separate components of Glx,we did not report individual values because of the substantial overlap ofthese multiplets at 1.5 T. Thus, we cannot identify what component of Glxwas elevated in BD patients. However, findings of decreased Glx measured inthe anterior cingulate cortex of medicated major depressive disorder patientshave been suggested to primarily reflect lowered glutamate levels.53 Future investigation using higher-field scannersmay improve deconvolution of the Glx spectral peaks and better address limitationsof spectral resolution at 1.5 T.
Other brain chemicals and T2r measures in both gray and white matterwere not significantly different between diagnostic groups. White-gray regressionslopes for chemical distributions between tissues are compatible with priorwork42-44 anddid not differentiate diagnostic groups, although BDI patients demonstratedan increased slope for lactate distribution between white and gray matter.Regional findings, although somewhat overlapping with the anatomic distributionfound in previous work,38,53-56 shouldbe interpreted conservatively. Further studies would be necessary to confirmregional Glx and NAA elevations observed in this BD sample.
Investigations of mood disorders using single-voxel 1H-MRspectroscopy have largely tested hypotheses of Cho alterations wherein bothregional elevations39,56,57 anddecreased Cho levels38,40,58 havebeen reported in association with depressed mood state. In our study, tissue-specificCho levels were not found to be altered in relationship to either BD diagnosisor mood state. We also did not find evidence of tissue-specific or regionalNAA reductions that have been reported in association with BD and perhapsmore specifically with psychosis.52,59-61 Variablefindings reported in the literature may reflect differences in clinical populations,medication status, brain regions studied, or MR spectroscopy acquisition parametersthat, in the setting of disease state–related T2 changes, as found forCho in this study, could substantially influence chemical concentration estimates.
In this study, mood-related findings of an inverse correlation for whitematter Cre with HAM-D scores are comparable with prior work that found decreasedphosphocreatine/Cre levels in association with depression.62,63 Inthis sample, the predominantly depressed or mixed-mood state of the BD patientslimits any relationship being identified between manic symptoms and chemicalalterations. A growing MR spectroscopy literature supports the presence ofbrain metabolic alterations in BD with variable relationships to mood state.Initial MR spectroscopy studies of BD used phosphorus P31 (31P)–labeledMR spectroscopy to evaluate brain energy and phospholipid metabolism.37 A meta-analysis of 8 31P-MR spectroscopystudies provides support for state-specific alterations of phospholipid membranesand high-energy phosphates in BD that primarily reflect increased phosphomonoesterlevels and decreased phosphocreatinine levels in the depressed state.54 Decreased phosphomonoester levels also have beenobserved in euthymic BDI patients, although not BDII patients, compared withHCs.62 More generally, findings of decreased βand total nucleotide triphosphate (primarily composed of adenosine triphosphate)provide evidence for abnormal brain energy metabolism in mood disorders.55,64 Because brain intracellular pH determinedby 31P-MR spectroscopy is found to be decreased in medication-freeBD patients in both manic and depressed mood states, as well as in euthymicBD patients stabilized with lithium treatment, metabolic aberrations may beintrinsic to the underlying pathophysiology of BD.65,66 Findingsof decreased frontal lobe intracellular pH in BD patients,65 consistentwith lactate acidosis, are postulated by those investigators to reflect underlyingmitochondrial dysfunction.66
It is possible that lactate elevations observed in this study couldreflect nonspecific manifestations of state-dependent anxiety, although participantsin our study did not report anxiety or any particular discomfort with beingin the scanner. Despite substantial baseline anxiety, we also do not typicallyobserve elevated baseline lactate levels in patients with panic disorder aboutto undergo a lactate infusion designed to induce panic.47,50,67,68 However,the diagnostic specificity of lactate and Glx findings remains uncertain.In a study using essentially the same methods, we observed no alterationsin either lactate or Glx in young children with autism.34 Onthe other hand, elevated lactate levels have also recently been found in associationwith first-break psychosis.69
Our findings of elevated gray matter lactate levels in the BD patientssuggest a shift in redox state from oxidative toward glycolytic energy utilization.Although its role in brain metabolism and homeostasis remains unresolved,70,71 earlier considerations of lactatebeing solely the by-product of anaerobic metabolism have been substantiallymodified by more recent work suggesting an important role for lactate in brainbioenergetics.72-74 Normalneuronal activation requires that some fraction of the energy expended comesfrom glycolysis. During rapid neuronal firing, coupled to increased extracellularglutamate levels, approximately one third of energy expenditure is estimatedto be contributed via glycolysis and increased lactate production.75 It is conceivable that increased or more sustainedrapid neuronal firing, possibly reflecting neuroexcitatory effects of increasedextracellular glutamate, with a resultant increased fraction of energy utilizationvia glycolysis, could explain the elevated gray matter lactate levels observedin BD patients. Because hypoperfusion is among the more consistent brain metabolicalterations found in BD,14,15,17 thisfactor could also contribute to, or account for, a shift in redox state towardglycolysis. Alternatively, or in conjunction with these considerations, recentin vivo evidence supports an association between elevated brain lactate andGlx levels and cyanide-induced inhibition of mitochondrial oxidative metabolism;mechanisms underlying brain glutamate increases are postulated to reflectalterations in the release and reuptake of glutamate that are dependent onintact oxidative metabolism.76
Elevated brain lactate is considered to be a sensitive marker for mitochondrialcompromise,77 but severe clinical manifestations(eg, MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke]syndrome) also are variably associated with reduced NAA levels.78 Althoughwe did not find evidence for reduced NAA in BD patients, this might reflectthe lesser severity of mitochondrial compromise speculated to account forlactate and Glx level elevations observed in our sample. The spectrum of clinicaland metabolic manifestations of mitochondrial dysfunction may reflect variableloading of mitochondrial DNA polymorphisms, some possibly linked to BD,79 that exhibit differing threshold response to oxidativestress.80 Phospholipid membrane alterationsfound in association with BD may also interfere with mitochondrial function,just as mitochondrial dysfunction can alter phospholipid metabolism.81-84
Considerations regarding the possible role of mitochondrial compromisein BD have important treatment implications; for example, evidence of thepossible neuroprotective properties of lithium,35,36,41 alsoobserved under conditions of elevated glutamate levels or ischemia, are hypothesized,in part, to be mediated through bcl-2 elevation, a neuroprotective proteinthat also has mitochondrial membrane-stabilizing effects.85 Althoughthe demonstration of causal relationships remains challenging, the presentwork suggests subtle alterations of energy metabolism in BD.
To summarize, gray matter lactate and Glx level elevations in medication-freeBD patients suggest altered cellular energy metabolism. These chemical alterations,suggestive of a redox shift toward glycolysis, may reflect a generalized patternof compromised mitochondrial metabolism in BD.
Corresponding author and reprints: Stephen R. Dager, MD, Universityof Washington Neuroimaging Research Group and the Center for Anxiety and Depression,1100 NE 45th Street, Suite 555, Seattle, WA 98105 (e-mail: srd@u.washington.edu).
Submitted for publication March 10, 2003; final revision received December18, 2003; accepted January 18, 2004.
This study was supported in part by grant RO1 MH58681 from the NationalInstitute of Mental Health, Bethesda, Md, and the Poitras Foundation and theStanley Foundation Bipolar Disorders Research Center at McLean Hospital, Boston,Mass.
We thank Marie Domsalla, Chris Budech, and Carolyn Bea for assistancein recruiting participants and organizational assistance. We also thank DeniseEchelard, Gerald Ortiz, and James Anderson for MR technical support.
1.American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders,Fourth Edition. Washington, DC American Psychiatric Association1994;
2.Dunner
DL Subtypes of bipolar affective disorder with particular regard to bipolarII.
Psychiatr Dev. 1983;175- 86
PubMedGoogle Scholar 3.Dunner
DL A review of the diagnostic status of "Bipolar II" for the DSM-IV workgroup on mood disorders.
Depression. 1993;12- 10
Google ScholarCrossref 4.Weissman
MMBland
RCCanino
GJFaravelli
CGreenwald
SHwu
HGJoyce
PRKaram
EGLee
CKLellouch
JLepine
JPNewman
SCRubio-Stipec
MWells
JEWickramaratne
PJWittchen
HYeh
EK Cross-national epidemiology of major depression and bipolar disorder.
JAMA. 1996;276293- 299
PubMedGoogle ScholarCrossref 5.Bland
RC Epidemiology of affective disorders: a review.
Can J Psychiatry. 1977;42367- 377
Google Scholar 6.Jamison
KRGoodwin
FK Manic Depressive Illness. New York, NY Oxford University Press1990;
8.Keck
PE
JrMcElroy
SL Outcome in the pharmacologic treatment of bipolar disorder.
J Clin Psychopharmacol. 1996;16
(2)
115S- 23S
PubMedGoogle ScholarCrossref 9.Bowden
CL Efficacy of lithium in mania and maintenance therapy of bipolar disorder.
J Clin Psychiatry. 2000;6135- 40
PubMedGoogle Scholar 10.Begley
CEAnnegers
JFSwann
ACLewis
CCoan
SSchnapp
WBBryant-Comstock
L The lifetime cost of bipolar disorder in the US: an estimate for newcases in 1998.
Pharmacoeconomics. 2001;19483- 495
PubMedGoogle ScholarCrossref 11.Wyatt
RJHenter
I An economic evaluation of manic-depressive illness—1991.
Soc Psychiatry Psychiatr Epidemiol. 1995;30213- 219
PubMedGoogle Scholar 12.Murray
CJLLopez
AD The Global Burden of Disease. Boston, Mass Harvard University Press1996;
13.Manji
HKLenox
RH Signaling: cellular insights into the pathophysiology of bipolar disorder.
Biol Psychiatry. 2000;48518- 530
PubMedGoogle ScholarCrossref 14.Baxter
LRPhelps
MEMazziotta
JCSchwartz
JMGerner
RHSelin
CESumida
RM Cerebral metabolic rates for glucose in mood disorders: studies withpositron emission tomography and fluorodeoxyglucose F 18.
Arch Gen Psychiatry. 1985;42441- 447
PubMedGoogle ScholarCrossref 15.Baxter
LRSchwartz
JMPhelps
MEMazziotta
JCGuze
BHSelin
CEGerner
RHSumida
RM Reduction of prefrontal cortex glucose metabolism common to three typesof depression.
Arch Gen Psychiatry. 1989;46243- 250
PubMedGoogle ScholarCrossref 16.Drevets
WCPrice
JLSimpson
JRTodd
RDReich
TVannier
MRaichle
ME Subgenual prefrontal cortex abnormalities in mood disorders.
Nature. 1997;386824- 827
PubMedGoogle ScholarCrossref 17.Ketter
TAKimbrell
TAGeorge
MSDunn
RTSpeer
AMBenson
BEWillis
MWDanielson
AFrye
MAHerscovitch
PPost
RM Effects of mood and subtype on cerebral glucose metabolism in treatment-resistantbipolar disorder.
Biol Psychiatry. 2001;4997- 109
PubMedGoogle ScholarCrossref 18.Strakowski
SMAdler
CMDelBello
MP Volumetric MRI studies of mood disorders: do they distinguish unipolarand bipolar disorder?
Bipolar Disord. 2002;480- 88
PubMedGoogle ScholarCrossref 19.Strakowski
SMDelBello
MPSax
KWZimmerman
MEShear
PKHawkins
JMLarson
ER Brain magnetic resonance imaging of structural abnormalities in bipolardisorder.
Arch Gen Psychiatry. 1999;56254- 260
PubMedGoogle ScholarCrossref 20.Zipursky
RBSeeman
MVBury
ALangevin
RWortzman
GKatz
R Deficits in gray matter volume are present in schizophrenia but notbipolar disorder.
Schizophr Res. 1997;2685- 92
PubMedGoogle ScholarCrossref 21.Lim
KORosenbloom
MJFaustman
WOSullivan
EVPfefferbaum
A Cortical gray matter deficit in patients with bipolar disorder.
Schizophr Res. 1999;40219- 227
PubMedGoogle ScholarCrossref 22.Lopez-Larson
MPDelBello
MPZimmerman
MESchwiers
MLStrakowski
SM Regional prefrontal gray and white matter abnormalities in bipolardisorder.
Biol Psychiatry. 2002;5293- 100
PubMedGoogle ScholarCrossref 23.Lyoo
IKKim
JMStoll
ALDemopulos
CParow
ADager
SRFriedman
SDDunner
DLRenshaw
PF Frontal lobe gray matter density decreases in bipolar disorders.
Biol Psychiatry. In press
Google Scholar 24.Altshuler
LLBartzokis
GGrieder
TCurran
JJimenez
TLeight
KWilkins
JGerner
RMintz
J An MRI study of temporal lobe structures in men with bipolar disorderor schizophrenia.
Biol Psychiatry. 2000;48147- 162
PubMedGoogle ScholarCrossref 25.Drevets
WCVideen
TOPrice
JLPreskorn
SHCarmichael
STRaichle
ME A functional neuroanatomy of unipolar depression.
J Neurosci. 1992;123628- 3641
PubMedGoogle Scholar 26.Sheline
YIGado
MHPrice
JL Amygdala core nuclei volumes are decreased in recurrent major depression.
Neuroreport. 1998;92023- 2028
PubMedGoogle ScholarCrossref 27.Hauser
PMatochik
JAltshuler
LLDenicoff
KDConrad
ALi
XHauser
PMatochik
J MRI-based measurements of temporal lobe and ventricular structuresin patients with bipolar I and bipolar II disorders.
J Affect Disord. 2000;6025- 32
PubMedGoogle ScholarCrossref 29.Schirmer
TAuer
DP On the reliability of quantitative clinical magnetic resonance spectroscopyof the human brain.
NMR Biomed. 2000;1328- 36
PubMedGoogle ScholarCrossref 30.Dager
SRSteen
RG Applications of MRS to the investigation of neuropsychiatric disorders.
Neuropsychopharmacology. 1992;6249- 266
PubMedGoogle Scholar 31.Soares
JCKrishnan
KRRKeshavan
MS Nuclear magnetic resonance spectroscopy: new insights into the pathophysiologyof mood disorders.
Depression. 1996;414- 30
PubMedGoogle ScholarCrossref 32.Lyoo
IKRenshaw
PF Magnetic resonance spectroscopy: current and future applications inpsychiatric research.
Biol Psychiatry. 2002;51195- 207
PubMedGoogle ScholarCrossref 33.Posse
SDager
SRRichards
TLYuan
CArtru
AAOgg
RArtru
AAMuller-Gartner
HWHayes
C
In vivo measurement of regional brain metabolicresponse to hyperventilation using functional proton echo-planar spectroscopicimaging (PEPSI).
Magn Reson Med. 1997;37858- 865
PubMedGoogle ScholarCrossref 34.Friedman
SDShaw
DWWArtru
AARichards
TLGardner
JDawson
GPosse
SDager
SR Regional brain chemical alterations in young children with autism spectrumdisorder.
Neurology. 2003;60100- 107
PubMedGoogle ScholarCrossref 35.Moore
GJBebchuk
JMHasanat
KChen
GSeraji-Bozorgzad
NWilds
IBFaulk
MWKoch
SGlitz
DAJolkovsky
LManji
HK Lithium increases N-acetyl-aspartate in the human brain:
in vivo evidence in support of bcl-2's neurotrophic effects?
Biol Psychiatry. 2000;481- 8
PubMedGoogle ScholarCrossref 36.Moore
GJBebchuk
JMWilds
IBChen
GManji
HKMenji
HK Lithium-induced increase in human brain gray matter.
Lancet. 2000;3561241- 1242
PubMedGoogle ScholarCrossref 37.Kato
TShioiri
TTakahashi
SInubushi
T Measurement of brain phosphoinositide metabolism in bipolar patientsusing
in vivo31P-MRS.
J Affect Disord. 1991;22185- 190
PubMedGoogle ScholarCrossref 38.Renshaw
PFLafer
BBabb
SMFava
MStoll
ALChristensen
JDMoore
CMYurgelun-Todd
DABonello
CMPillay
SSRothschild
AJNierenberg
AARosenbaum
JFCohen
BM Basal ganglia choline levels in depression and response to fluoxetinetreatment: an
in vivo proton magnetic resonance spectroscopystudy.
Biol Psychiatry. 1997;41837- 843
PubMedGoogle ScholarCrossref 39.Charles
HCLazeyras
FKrishnan
KRRBoyko
OBPayne
MMoore
D Brain choline in depression:
in vivo detectionof potential pharmacodynamic effects of antidepressant therapy using hydrogenlocalized spectroscopy.
Prog Neuropsychopharmacol Biol Psychiatry. 1994;181121- 1127
PubMedGoogle ScholarCrossref 40.Sonawalla
SBRenshaw
PFMoore
CMAlpert
JENierenberg
AARosenbaum
JFFava
M Compounds containing cytosolic choline in the basal ganglia: a potentialbiological marker of true drug response to fluoxetine.
Am J Psychiatry. 1999;1561638- 1640
PubMedGoogle Scholar 41.Sassi
RBNicoletti
MBrambilla
PMallinger
AGFrank
EKupfer
DJKeshavan
MSSoares
JC Increased gray matter volume in lithium-treated bipolar disorder patients.
Neurosci Lett. 2002;329243- 245
PubMedGoogle ScholarCrossref 42.Lim
KOSpielman
DM Estimating NAA in cortical gray matter with applications for measuringchanges due to aging.
Magn Reson Med. 1997;37372- 377
PubMedGoogle ScholarCrossref 43.Doyle
TJBedell
BJNarayana
PA Relative concentrations of proton MR visible neurochemicals in grayand white matter in human brain.
Magn Reson Med. 1995;33755- 759
PubMedGoogle ScholarCrossref 44.Pfefferbaum
AAdalsteinsson
ESpielman
DSullivan
EVLim
KO
In vivo spectroscopic quantification of theN-acetyl moiety, creatine, and choline from large volumes of brain gray andwhite matter: effects of normal aging.
Magn Reson Med. 1999;41276- 284
PubMedGoogle ScholarCrossref 46.Young
RCBiggs
JTZiegler
VEMeyer
DA A rating scale for mania: reliability, validity, and sensitivity.
Br J Psychiatry. 1978;133429- 435
PubMedGoogle ScholarCrossref 47.Dager
SRFriedman
SDHeide
ALayton
MERichards
TLArtru
AAStrauss
WHayes
CPosse
S Two-dimensional proton echo-planar spectroscopic imaging (PEPSI) ofbrain metabolic changes during lactate-induced panic.
Arch Gen Psychiatry. 1999;5670- 77
PubMedGoogle ScholarCrossref 48.Provencher
SW Estimation of metabolite concentrations from localized
in vivo proton NMR spectra.
Magn Reson Med. 1993;30672- 679
PubMedGoogle ScholarCrossref 49.Barker
PTSoher
BJBlackband
SJChatham
JCMathews
VPBryan
RN Quantitation of proton NMR spectra of the human brain using tissuewater as an internal concentration reference.
NMR Biomed. 1993;689- 94
PubMedGoogle ScholarCrossref 50.Friedman
SDDager
SRRichards
TLPetropoulos
HPosse
S Modeling brain compartmental lactate response to metabolic challenge.
Psychiatry Res Neuroimaging. 2000;9855- 66
PubMedGoogle ScholarCrossref 51.Castillo
MKwock
LCourvoisie
HHooper
SR Proton MR spectroscopy in children with bipolar affective disorder:preliminary observations.
AJNR Am J Neuroradiol. 2000;21832- 838
PubMedGoogle Scholar 52.Cecil
KMDelBello
MPMorey
RStrakowski
SM Frontal lobe differences in bipolar disorder as determined by protonMR spectroscopy.
Bipolar Disord. 2002;4357- 365
PubMedGoogle ScholarCrossref 53.Auer
DPPütz
BKraft
ELipinski
BSchill
JHolsboer
F Reduced glutamate in the anterior cingulate cortex in depression: an
in vivo proton magnetic resonance spectroscopy study.
Biol Psychiatry. 2000;47305- 313
PubMedGoogle ScholarCrossref 54.Yildiz
ASachs
GSDorer
DJRenshaw
PF
31P nuclear magnetic resonance spectroscopy findings inbipolar illness: a meta-analysis.
Psychiatry Res. 2001;106181- 191
PubMedGoogle ScholarCrossref 55.Moore
CMChristensen
JDLafer
BFava
MRenshaw
PF Lower levels of nucleoside triphosphate in the basal ganglia of depressedsubjects: a phosphorous-31 magnetic resonance spectroscopy study.
Am J Psychiatry. 1997;154116- 118
PubMedGoogle Scholar 56.Hamakawa
HKato
TMurashita
JKato
N Quantitative proton magnetic resonance spectroscopy of the basal gangliain patients with affective disorders.
Eur Arch Psychiatry Clin Neurosci. 1998;24853- 58
PubMedGoogle ScholarCrossref 57.Steingard
RJYurgelun-Todd
DAHennen
JMoore
JCMoore
CMVakili
KYoung
ADKatic
ABeardslee
WRRenshaw
PF Increased orbitofrontal cortex levels of choline in depressed adolescentsas detected by
in vivo proton magnetic resonancespectroscopy.
Biol Psychiatry. 2000;481053- 1061
PubMedGoogle ScholarCrossref 58.Ende
GBraus
DFWalter
SWeber-Fahr
WHenn
FA The hippocampus in patients treated with electroconvulsive therapy:a proton magnetic resonance spectroscopic imaging study.
Arch Gen Psychiatry. 2000;57937- 943
PubMedGoogle ScholarCrossref 59.Winsberg
MESachs
NTate
DLAdalsteinsson
ESpielman
DKetter
TA Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder.
Biol Psychiatry. 2000;47475- 481
PubMedGoogle ScholarCrossref 60.Deicken
RFPegues
MPAnzalone
SFeiwell
RSoher
B Lower concentration of hippocampal N-acetylaspartate in familial bipolarI disorder.
Am J Psychiatry. 2003;160873- 882
PubMedGoogle ScholarCrossref 61.Chang
KAdleman
NDienes
KBarnea-Goraly
NReiss
AKetter
T Decreased N-acetylaspartate in children with familial bipolar disorder.
Biol Psychiatry. 2003;531059- 1065
PubMedGoogle ScholarCrossref 62.Kato
TTakahashi
SShioiri
TMurashita
JHamakawa
HInubushi
T Reduction of brain phosphocreatine in bipolar-II disorder detectedby phosphorous-31 magnetic resonance spectroscopy.
J Affect Disord. 1994;31125- 133
PubMedGoogle ScholarCrossref 63.Hamakawa
HKato
TShioiri
TInubushi
TKato
N Quantitative proton magnetic resonance spectroscopy of the bilateralfrontal lobes in patients with bipolar disorder.
Psychol Med. 1999;29639- 644
PubMedGoogle ScholarCrossref 64.Volz
HPRzanny
RRiehemann
SMay
SHegewald
HPreussler
BHubner
GKaiser
WASauer
H
31P magnetic resonance spectroscopy in the frontal lobeof major depressed patients.
Eur Arch Psychiatry Clin Neurosci. 1998;248289- 295
PubMedGoogle ScholarCrossref 65.Kato
TMurashita
JKamiya
AShioiri
TKato
NInubushi
T Decreased brain intracellular pH measured by
31P-MRS inbipolar disorder: a confirmation in drug-free patients and correlation withwhite matter hyperintensity.
Eur Arch Psychiatry Clin Neurosci. 1998;248301- 306
PubMedGoogle ScholarCrossref 67.Dager
SRMarro
KIMetzger
GDRichards
TL Preliminary applications of magnetic resonance spectroscopy to investigatelactate-induced panic.
Am J Psychiatry. 1994;15157- 63
PubMedGoogle Scholar 68.Dager
SRRichards
TStrauss
WLArtru
A Single-voxel
1H MRS investigation of brain metabolic changesduring lactate-induced panic.
Psychiatry Res. 1997;7689- 99
PubMedGoogle ScholarCrossref 69.Renshaw
PFYurgelun-Todd
DAWei
HCharles
HCTohen
MSharma
TZipursky
RBKahn
RGur
REGreen
AJMcEvoy
JPPerkins
DOHamer
RMNemeroff
CBRothschild
AJKuldau
JMStrakowski
SMTollefson
GDLieberman
JA Olanzapine induced reductions in frontal lobe lactate levels correlatewith treatment response in first episode psychosis.
Biol Psychiatry. 2003;53suppl67S
Google Scholar 70.Chih
CLipton
PRoberts
EL Do active cerebral neurons really use lactate rather than glucose?
Trends Neurosci. 2001;24573- 578
PubMedGoogle ScholarCrossref 71.Takata
TSakurai
TYang
BYokono
KOkada
Y Effect of lactate on the synaptic potential, energy metabolism, calciumhomeostasis and extracellular glutamate concentration in the dentate gyrusof the hippocampus from guinea-pig.
Neuroscience. 2001;104371- 378
PubMedGoogle ScholarCrossref 72.Tsacopoulos
MMagistretti
PJ Metabolic coupling between glia and neurons.
J Neurosci. 1996;16877- 885
PubMedGoogle Scholar 74.Smith
DPernet
AHallett
WABingham
EMarsden
PKAmiel
SA Lactate: a preferred fuel for human brain metabolism
in vivo. J Cereb Blood Flow Metab. 2003;23658- 664
PubMedGoogle ScholarCrossref 75.Shulman
RGHyder
FRothman
DL Cerebral energetics and the glycogen shunt: neurochemical basis offunctional imaging.
Proc Natl Acad Sci U S A. 2001;986417- 6422
PubMedGoogle ScholarCrossref 76.Clausen
TZauner
ALevasseur
JERice
ACBulluck
R Induced mitochondrial failure in the feline brain: implications forunderstanding acute post-traumatic metabolic events.
Brain Res. 2001;90835- 48
PubMedGoogle ScholarCrossref 77.Lin
DDCrawford
TOBarker
PB Proton MR spectroscopy in the diagnostic evaluation of suspected mitochondrialdisease.
AJNR Am J Neuroradiol. 2003;2433- 41
PubMedGoogle Scholar 80.Calabrese
VSeapagnini
GStella
AM GiuffridaBates
TEClark
JB Mitochondrial involvement in brain function and dysfunction: relevanceto aging, neurodegenerative disorders and longevity.
Neurochem Res. 2001;26739- 764
PubMedGoogle ScholarCrossref 81.Nakahara
IKikuchi
HTaki
WNishi
SKito
MYonekawa
YGoto
YOgata
N Changes in major phospholipids of mitochondria during postischemicreperfusion in rat brain.
J Neurosurg. 1992;76244- 250
PubMedGoogle ScholarCrossref 82.Farber
SASlack
BEBlusztan
JK Acceleration of phospatidylcholine synthesis and breakdown by inhibitorsof mitochondrial function in neuronal cells: a model of the membrane defectof Alzheimer's disease.
FASEB J. 2000;142198- 2206
PubMedGoogle ScholarCrossref 83.Piccotti
LMarchetti
CMigliorati
GRoberti
RCorazzi
L Exogenous phospholipids specifically affect transmembrane potentialof brain mitochondria and cytochrome C release.
J Biol Chem. 2002;27712075- 12081
PubMedGoogle ScholarCrossref 84.Modica-Napolitano
JSRenshaw
PF Ethanolamine and phosphoethanolamine inhibit mitochondrial bioenergeticfunction
in vitro: implications for mitochondrialdysfunction hypothesis in depression and bipolar disorder.
Biol Psychiatry. 2004;55273- 277
PubMedGoogle ScholarCrossref 85.Manji
HKMoore
GJChen
G Clinical and preclinical evidence for the neurotrophiceffects of mood stabilizers: implications for the pathophysiology and treatmentof manic-depressive illness.
Biol Psychiatry. 2000;48740- 754
PubMedGoogle ScholarCrossref